# Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder

> **NCT04169360** · PHASE2 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Opioid-use Disorder

## Interventions

- **DRUG:** ANS-6637
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04169360
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01
- **Primary completion:** 2021-01-12
- **Final completion:** 2021-01-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The FDA determined that there is not adequate safety information to continue clinical investigations using ANS-6637 and Amygdala Neurosciences, the product company of ANS-6637, is no longer pursuing research with this compound.
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04169360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04169360, "Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04169360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*